Cogent Biosciences FDA Milestones Put Bezuclastinib And Valuation In Focus [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
Cogent Biosciences received FDA Breakthrough Therapy Designation for bezuclastinib in combination with sunitinib in gastrointestinal stromal tumors (GIST). The FDA also accepted Cogent's New Drug Application for bezuclastinib into the Real-Time Oncology Review program. These regulatory updates highlight potential changes for future treatment options in GIST if the drug is ultimately approved. Cogent Biosciences, traded as NasdaqGS:COGT, is drawing fresh attention with these back to back regulatory milestones. The stock closed at $35.91, and the 1 year return of 299.4% and 5 year return of 238.8% indicate that the share price has been sensitive to clinical and regulatory catalysts. For you as an investor, the key question is how these FDA programs might affect timing and visibility around bezuclastinib. The company's recent regulatory progress may keep focus on upcoming FDA interactions and any new data readouts tied to GIST treatment. Stay updated on the most important news
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD) [Yahoo! Finance]Yahoo! Finance
- Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences (NASDAQ:COGT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=COGT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Cogent Biosciences announcse U.S. BTD for bezuclastinib [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)GlobeNewswire
COGT
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/22/26 - Form 4
- 1/22/26 - Form 144
- COGT's page on the SEC website